Suven Life Sciences receives product patents in Eurasia, Japan and Mexico

Pharmaceutical firm Suven Life Sciences today said it has been granted product patents by Eurasia, Japan and Mexico for a drug used in the treatment of neurodegenrative diseases, which include Alzheimer's disease, Schizophrenia and Parkinson's disease.

According to the company's BSE filing, it has been granted "one product patent from Eurasia, one from Japan and one product patent from Mexico for the new chemical entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases".
The company said the patents would be valid until 2029.

Suven Life Sciences CEO Venkat Jasti said the company was pleased with the grant of the patents for its pipeline of molecules in the CNS (central nervous system) arena that were being developed for cognitive disorders with high unmet need with huge market potential globally.

With the new patents, Suven has a total of 13 granted patents 13 from Eurasia, 12 from Japan and 17 from Mexico.

"These patents are exclusive intellectual property of Suven...Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-1 and Phase-2," Suven Life Sciences said.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven reported.